​ArisiTol, Others Surge in US CBD Market; Will B.C.’s Cannabis Technologies Be the New GW Pharma?

Notice the uptick on both stocks on the 28 th as the news spread about UofA rejecting the PTSD CBD study. What is not easily shown in charts and headlines is that Dr. Sisley intends to use the actual plant constituents to complete her study, not a biochemical Frankenstein by GWP or CTI. This sets her aside from Epidolex and Sativex

Read Full Story >>
The story is too old to be commented.